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Primary medical prevention of cardiovascular disease (CVD) has received low priority in Tanzania,
despite evidence of the rising prevalence of CVD risk factors. Different guidelines have been proposed for
medical CVD prevention, including the European Society of Cardiology (ESC) and the World Health Or-
ganization (WHO) guidelines, which recommend medical prevention for all individuals based on the
consideration of single CVD risk thresholds. A third alternative is differentiated risk thresholds according
to age. This paper compares the WHO and the differentiated risk threshold by age approaches against a
baseline of no medical CVD prevention and a best scenario identical to the ESC approach in Tanzania.
Assuming ﬁxed budgets, we evaluate the guidelines according to three outcome measures, namely: ef-
ﬁciency, inequality and the combination of efﬁciency and inequality.
We ran a Markov analysis for an estimated Tanzanian population at risk of CVD employing a 40 years
time horizon to estimate the total expected costs and CVD deaths associated with provision of the
different guidelines. The results were then used to calculate three outcomes: life expectancy at age 40 as
a proxy for efﬁciency, the Gini coefﬁcient (a measure of inequality), and the achievement index (which
combines concerns of efﬁciency and inequality).
Our results suggest that higher life expectancy (28.3 vs. 26.6 years) and more equally distributed
health (Gini coefﬁcient of 0.22 vs. 0.24) could be attained if medical CVD prevention was based on the
differentiated risk threshold approach compared to the WHO single risk threshold, when the total cost of
these approaches is the same.
Preventing CVD based on differentiating risk thresholds by age seems to be the better alternative when
concerns of both efﬁciency and inequality are considered important. However, further research on the
country-speciﬁc distribution of CVD risk levels and budget impact analysis are important to assess the
feasibility of its implementation.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The risk of cardiovascular disease (CVD) in many sub-Saharan
African countries (SSA) is increasing (Dalal et al., 2011), and
Tanzania is not different in this regard (Aspray et al., 2000; Bovet
et al., 2002; Edwards et al., 2000; Hendriks et al., 2012; Njelekela
et al., 2001, 2003, 2009). As such, the burden of disease caused byic Health and Primary Health
4, NO-5020, Bergen, Norway.
o, fngalesoni@gmail.com
r Ltd. This is an open access article umyocardial infarction (MI) and stroke, which are the two main
forms of CVD, has increased by 60% in Tanzania during the period
1990 to 2013 (Institute of Health Metrics and Evaluation, 2013).
CVD are projected to increase further in developing countries over
the next 10e15 years (Kearney et al., 2005; Shaw et al., 2010).
Despite this increasing burden, primary prevention of CVD has
lagged behind in the region. It receives low priority in research and
policy documents, and is often practiced in a non-systematic and
fragmentary way (World Health Organization, 2015). These prac-
tices of considering only one or two individual risk factors, for
instance blood pressure levels and/or cholesterol levels (which wender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ering other related factors e.g. age, smoking status etc.ecan be
inefﬁcient and in most cases lead to the over treatment and under
treatment of some relatively low-risk and high-risk patients,
respectively (Cobiac et al., 2012; Gaziano, 2007). Individual risk
factor approach will therefore not be discussed further in this pa-
per. An alternative approach recommended by the World Health
Organization (WHO) and elsewhere (Cobiac et al., 2012; Ferket
et al., 2010; Gaziano, 2007; Gaziano et al., 2005; World Health
Organization, 2007) is based on the fact that the probability of a
CVD event depends on many factors. This approach (which has
been termed the absolute risk approach) combines major modiﬁ-
able factors including hypertension, cholesterol level, and smoking
and unmodiﬁable factors like age and sex to give the probability of a
CVD event occurring in a given time period, e.g. ten years, which
then forms the basis for the initiation of medical CVD primary
prevention (National Vascular Disease Prevention Alliance, 2014).
There are two different principles to the absolute risk approach
which will be further scrutinized in this work. These are: (i) ab-
solute risk based on single risk threshold, which is the commonest
and has been the basis of the WHO and the European Society for
Cardiology (ESC) guidelines, and (ii) absolute risk based on differ-
entiated risk thresholds, as used in Norway.
1.1. Single risk threshold approaches
1.1.1. The WHO approach
The WHO has developed risk prediction charts for its regions,
which use easily measurable indicators to obtain probabilities of
CVD events (see Appendix 1). These tools are especially useful for
low-income settings where capacity and resources are lacking to
support the development of population-speciﬁc risk prediction
charts. These charts group individuals into four CVD levels ac-
cording to their 10-year absolute risk of a CVD event, namely: low
risk (<9.9%), moderate risk (10e19.9%), high risk (20e29.9%), and
very high risk (30%). The WHO then recommends medical pre-
vention to those with moderate, high and very high absolute CVD
risk levels, unless they are diabetic or other factors e.g. renal
impairment exists, which makes medical management necessary
regardless of CVD risk level (World Health Organization, 2007). The
terms “10-year risk of a CVD event” and “risk threshold” are used
interchangeably in this paper.
1.1.2. The ESC approach
The ESC guidelines use the same absolute risk approach in their
guide to medical interventions to prevent CVD (see Appendix 2).
Although the current version of the guidelines avoids being explicit
about the threshold values that qualify individuals for medical
intervention, it states that, in general, individuals with absolute risk
of a CVD event of 5e9.9% may beneﬁt from or frequently require
medical prevention (Perk et al., 2012). It may not be pragmatic for
Tanzania to adopt this policy of using low threshold values as the
basis for medical CVD prevention due to its resource-constrained
health system; however, it will be interesting to assess this
approach as a best-case scenario comparator. We chose to deﬁne
the WHO and ESC guidelines as single risk threshold guidelines
since medical management decisions are based on one (single)
threshold range irrespective of age.
1.2. Risk thresholds differentiated by age approach
Norway has chosen to divert from this single risk approach
(having only one risk threshold irrespective of age) to a differen-
tiated risk threshold approach (having different risk thresholds
according to age). With the differentiated risk threshold approach,lower risk thresholds are assigned to younger age groups and
higher risk thresholds to older ones (Norheim et al., 2011). Age is
therefore used directly to predict the absolute risk of a CVD event
and indirectly to determine the cut-off point for eligibility for
medical CVD prevention. This follows concerns that the ESC
guidelines would classify most elderly people as being eligible for
medical prevention of CVD since the estimated CVD risk of an event
(in these age categories) will often exceed the 5% level based on age
and gender alone, even when other cardiovascular risk factors are
relatively low (Getz et al., 2004; Graham et al., 2007; Hartz et al.,
2005; Norheim et al., 2011). The current version of the ESC guide-
lines has attempted to deal with this challenge by introducing the
concept of “cardiovascular risk age”, whereby the risk age of a
person with several cardiovascular risk factors is equated with the
age of a person with the same level of risk but with ideal levels of
risk factors. For example, a hypertensive, smoking 40-year-old man
can be considered to have a cardiovascular risk age similar to that of
a normotensive, non-smoking 60-year-old man. However, this risk
age is not currently used as a basis to determine eligibility for
medical prevention of CVD (Perk et al., 2012).
There is vast evidence that CVD risk factors, e.g. use of tobacco, are
high and becoming more prevalent in disadvantaged people of low
socioeconomic status, as well as for low-income countries (LICs).
Consequently, CVD affect these disadvantaged groups dispropor-
tionately (Mendis et al., 2011). Even though country-level evidenceon
the impact of inequalities associated with CVD in Tanzania is lacking,
these trends are likely to apply to many LICs, including Tanzania.
The aim of this study is to compare the potential impact of two
absolute risk approaches to deﬁnemedication eligibility: (i) theWHO
approach (risk threshold 10e19.9%) and (ii) the risk threshold
differentiated by age. In both cases, we assume budgets to be con-
stant (exogenous) and limited. Both alternatives are compared
against (iii) a baseline scenario of nomedical CVDprevention and (iv)
a base-case scenario identical to the ESC approach (risk threshold
5e9.9%). We evaluate all four scenarios according to efﬁciency,
inequality and the combination of efﬁciency and inequality.
1.3. Analytical framework
Health maximization and fair distribution are key principles for
priority setting in health care in a number of countries. Oper-
ationalizing the health maximization principle by quantifying the
costs of an activity relative to its beneﬁts, for example in cost-
effectiveness analysis (CEA), is practiced in countries such as the
UK and USA (NICE, 2014; Sullivan et al., 2009), and also by theWHO
through the CHOICE project (CHOosing Interventions that are Cost-
Effective) (World Health Organization, 2014a). The health maxi-
mization principle has been criticized for ignoring the distribution
of health beneﬁts (World Health Organization, 2014b).
The distribution of health outcomes, on the other hand, is rarely
quantiﬁed and is thus given less weight in actual priority setting
(Norheim et al., 2014; Robberstad andNorheim, 2011;World Health
Organization, 2014b). Distributional concerns can be motivated by
twomain arguments: egalitarianism (aversion to health inequality)
and prioritarianism (a special concern for the worst off) (Bognar
and Hirose, 2014; Brock and Wikler, 2006; Parﬁt, 1991, 1997;
Persad et al., 2009). Both arguments value equality (however
deﬁned) but in different ways. For egalitarians, equality is directly
important while for prioritarians, raising the position of the worst
off will in many instances reduce inequality, but not always
(Temkin, 1993). This implies that equality is valued indirectly in
prioritarianism (Parﬁt, 1991, 1997). Issues of who are the worst off
and how much priority they should be given continues to attract
much attention in the literature (Bognar and Hirose, 2014; Brock
and Wikler, 2006). Norwegian experts have justiﬁed their
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distributive grounds (Norheim et al., 2011).
There are two distinct approaches to measuring health in-
equalities; overall (pure) inequality and social group inequality. The
overall approach measures inequalities in the resulting distribution
of health for all individuals in the general population, ignoring the
determinants of health. The social group approach measures in-
equalities in the distribution of health according to some measure
of socioeconomic status, e.g. income, wealth or education (Wagstaff
and Doorslaerv, 2004). We are not considering socioeconomic
status in this study and will therefore focus on overall health
inequality. We do so becausewe did not have access to suitable data
for modeling differential impacts by socioeconomic status.
It is now widely acknowledged that decision-makers may wish
to combine concerns for health maximization with concerns for
health distribution in the overall judgement of population health.
Hence, consistent priority setting implies a need to quantify both
types of outcomes to enable a trade-off between the two (Brock and
Wikler, 2006; James et al., 2005; Norheim, 2014; Robberstad and
Norheim, 2011; Williams and Cookson, 2006; World Health
Organization, 2014b). Several proposals for taking into account
both maximization and distributional concerns have been put for-
ward. These include extending traditional cost-effectiveness anal-
ysis in twoways, by examining (i) ﬁnancial risk protection effects as
well as health effects, and (ii) the distribution of effects as well as
total effects. This approach has been labelled “extended” cost-
effectiveness analysis (Verguet et al., 2015). Another recent
approach goes further and seeks to integrate distributional con-
cerns into cost-effectiveness analysis (in what Asaria and col-
leagues term “distributional” cost-effectiveness analysis) through
inequality indices and social welfare functions (Asaria et al., 2013).
Integrating inequality aversion into a health-related social welfare
function was ﬁrst suggested by Anand and Wagstaff (Sudhir et al.,
2001; Wagstaff, 2002b). The present study performs a distribu-
tional cost-effectiveness analysis using the Gini Index to quantify
health inequality outcomes and the Achievement Index to integrate
health inequality outcomes with total health outcomes.
2. Methodology
2.1. Analytical modeling
We used a simpliﬁed version of a previously published Markov
model (Fig. 1) constructed in TreeAge Pro 2014 to analyze a closed
hypothetical Tanzanian cohort of individuals having no previous
history of MI or stroke (Ngalesoni et al., 2016).
The Markov analysis was run separately for the cohort of in-
dividuals having the three different CVD risk levels (low, moderate
and high). For simplicity we choose to omit the very high CVD risk
level. Each sub-cohortentered the six-statemodel (“nopreviousMIor
stroke”, “history of MI”, “history of mild stroke”, “history of moderate
stroke”, “history of severe stroke” and “death”) at the age of 40 years
and transited between the different health states in annual cycles
according to age-speciﬁc risks forMI and strokeanddependingon the
risk reduction from medical interventions following each of the four
CVD preventive scenarios analyzed (see Fig. 2).
All model inputs (costs, effectiveness, disability weights and
other transition probabilities) were based on two previous papers
on the cost and CEA of medical preventive strategies for CVD in
Tanzania. Brieﬂy, the cost estimates were estimated in the Tanza-
nian ﬁnancial year 2011/2012 following a “narrow” societal
perspective whereby only healthcare provider and patient costs
were included. The other model inputs were extracted from rele-
vant literature (Ngalesoni et al., 2014, 2016). Additional information
on the number of Tanzanians with low, moderate and high CVD risklevels was required to estimate the total costs and health outcomes
(CVD deaths) for each of the CVD preventive approaches analyzed.
We applied the CVD risk level distribution for Africa region E re-
ported in the WHO prevention of CVD guidelines (World Health
Organization, 2007) to the Tanzanian population according to
recent census data (National Bureau of Statistics Tanzania, 2013) to
obtain such ﬁgures. These are presented in Table A.3 under
Appendix 3. A time horizon of 40 years was applied, after which
only a negligible proportion of the cohort was still alive.
Model outputs, i.e. total costs andCVDdeaths,were thenextracted
from the Markov analysis output at the end of all cycles across the
three CVD risk levels following the baseline, WHO, differentiated risk
threshold and ESC approaches. Sincewe are comparing theWHO and
the differentiated risk threshold by age approaches, assuming a con-
stant and limited budget, we slightly reduced the coverage level of
medical CVD prevention management following the differentiated
risk threshold approach from the assumed 100% to about 84% so that
the costs of these two approaches are equalized.
2.2. Baseline approach
For the baseline approach, no medical prevention is provided for
any of the three CVD risk levels analyzed. This scenario almost re-
sembles the current situation in Tanzania, where preventive services
to individualsat riskarenot systematicallyprovided to thepopulation.
In the analysis of this approach, the threeCVDrisk level cohorts transit
through themodel with no adjustments to their risk of MI and stroke
since no medical intervention is provided (light grey area on Fig. 2).
2.3. WHO approach (risk threshold 10e19.9%)
For theWHO approach, the cohort of low CVD risk (risk threshold
<9.9%) transits through the model with their risk of MI and stroke
remaining unadjusted (grey area in Fig. 2). The risks of disease (MI
and stroke) for moderate and high CVD risk cohorts (risk threshold
of 10e19.9% and 20e29.9% respectively) were adjusted according to
the efﬁcacy of the drug combinations which had the most favorable
incremental cost-effectiveness ratio (ICER) from previous work on
CEA of medical strategies to prevent CVD in Tanzania (Ngalesoni
et al., 2016) (dark grey areas in Fig. 2 and Table 1).
2.4. Differentiated risk threshold by age
For this approach we applied different risk thresholds to
different age groups such that medical preventive interventions are
provided to:
 40e49 years: if risk threshold is  5e9.9%
 50e69 years: if risk threshold is  10e19.9%
 70e79 years: if risk threshold is  20e29.9%
This means that the 40e49 year olds transited the model with
their risk of disease adjusted by the most cost-effective medical
interventions (see Table 1). For the 50e69 and 70e79 year olds, risk
thresholds of 10e19.9% and 20e29.9%, respectively, were
required before risks were adjusted medically in our model (light
grey areas in Fig. 2).
2.5. ESC approach (risk threshold  5e9.9%)
For this approach, we assumed a base-case scenario in which
Tanzania is willing to paymore than one GDP per capita for a unit of
health gain such that it would become “very cost-effective” to treat
all individuals with 10-year risk of a CVD event (risk threshold)
equal to or above 5%. In examining the equity impact of this
Fig. 1. Simpliﬁed Markov model structure for WHO approach (risk threshold 10e19.9%).
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Fig. 2) transit through the model with their risk of MI and stroke
adjusted by efﬁcacy of the medical interventions recommended for
a particular CVD risk level in the previous cost-effectiveness study
(Table 1) (Ngalesoni et al., 2016).
For the WHO, differentiated risk threshold and ESC approaches,
we assume that theCVDprediction charts rightly classifycohorts into
correct risk level category in accordance to their CVD risk factors.
2.6. Equity analysis
2.6.1. Outcomes of interest
We analyzed equity and efﬁciency according to three outcomesBaseline approach ESC approach 
(risk threshold ≥5–9.9%) 
Low  Mod High Low Mod High
40-49 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
50-59 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
60-69 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
70-79 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
Low=low CVD risk level (10-year risk of a CVD event of 
of a CVD event of 10–19.9%); High=high CVD risk l
λ=Average 10-year risk of a CVD event for a particular C
medical management;          CVD primary prevention interv
Fig. 2. Risk threshold approaches to medicaof interest. These were: (i) life expectancy at age 40, as a proxy of
efﬁciency; (ii) inequality in life expectancy at age 40, using the Gini
coefﬁcient; and (iii) achievement index, which is a proxy
combining concern for both efﬁciency and inequality. From this
point onwards, we will use life expectancy to refer to life expec-
tancy at age 40.2.7. Life expectancy
Life expectancies were derived from the age-speciﬁc CVD deaths
obtained from the Markov analysis.WHO approach Differentiated risk threshold
(risk threshold 10–19.9%)  by age 
Low Mod High Low Mod High
 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
 λ=5% λ=15% λ=25% λ=5% λ=15% λ=25%
<9.9%); Mod=moderate CVD risk level (10-year risk 
evel (10-year risk of a CVD event of 20–29.9%); 
VD risk level;         No CVD primary prevention by 
ention 
l prevention of cardiovascular diseases.
Table 1
Drug combination used (*) in applying different risk thresholds to medical pre-
vention of CVD.
Strategy Cost Incr. cost Effectiveness Incr.
effectiveness
ICER
Low risk
No treatment 461 0.00
ACEI_Diu* 1005 544 0.41 0.41 1347
ACEI_Diu_Sta 1259 254 0.49 0.08 3175
Moderate risk
No treatment 1516 0.00
ACEI_Diu* 1683 167 1.02 1.02 164
ACEI_Diu_Sta 1827 144 1.28 0.26 554
High risk
No treatment 1695 0.00
ACEI_CCB_Diu* 2240 545 1.56 1.56 349
ACEI_CCB_Diu_Sta 2404 164 1.83 0.27 607
Incr ¼ Incremental; ICER¼Incremental cost-effectiveness ratio; ACEI ¼ Angiotensin
converting enzyme inhibitor; Diu ¼ Thiazide diuretic; Sta ¼ Statin; CCB¼Calcium
channel blockers; ASA ¼ Soluble aspirin; Interventions are said to be “very cost-
effective” if their ICER  some willingness to pay value (assumed to be US$610,
which is Tanzania's Gross Domestic Product (GDP) per capita for 2012). These results
are based on a paper on cost-effectiveness analysis of medical interventions in
Tanzania (Ngalesoni et al., 2016).
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For each of the four medical CVD preventive scenarios analyzed,
we employed Wagstaff's standard Gini coefﬁcient (Wagstaff,
2002b) using the formula below:
G ¼ 1
Pn
i¼1

R2i  ðRi  1Þ2

hi
n2mðhÞ
where n is the subset of the at-risk population that experienced
CVD death, m (h) is the average health of this population expressed
as average life expectancy, hi is the life expectancy for individual i
and Ri is the relative rank of the ith individual. The coefﬁcient is
bound between 0 and 1, where 0 describes perfect equality and 1
describes perfect inequality (Wagstaff, 2002b).
2.7.2. Achievement index
We adopted Wagstaff's proposition of integrating aversion to
inequality into a social welfare function framework in a measure he
calls the achievement index (A) (Wagstaff, 2002b). The achieve-
ment index can simply be understood as health adjusted for
inequality or, in our case, inequality-adjusted life expectancy. This
was calculated as follows:
A ¼
Pn
i¼1

Rvi  ðRi  1Þv

hi
nv
¼ mðhÞð1 GÞ
Inwhich hi reﬂects ex post estimates of life expectancy from our 20
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Fig. 3. Annual number of deaths when different risk thMarkov model, and parameter v represents the degree of overall
equality aversion. Values > 1 indicate preferences in favor of giving
more weight to the worse-off (lower ranked) individuals compared
to better-off (higher ranked) individuals. In this work, we assume
v ¼ 2.
3. Ethical statement
Ethical clearancewas provided by the Ethical Review Committee
of the Tanzania National Institute of Medical Research with Ref. No.
NIMR/HQ/R.8 a/Vol. IX/1364. Respondents from the health facilities
involved were asked for their consent to participate in the study
and written permission was obtained prior to the interviews.
4. Results
4.1. Number of deaths
The number of annual CVD deaths was found to increase as the
cohort grows older, irrespective of risk approach. When the two
absolute risk approaches are compared, the WHO approach resul-
ted in the highest mortality amongst young age groups and lowest
mortality amongst old age groups compared to the differentiated
risk threshold by age approach (Fig. 3).
It is interesting to note that the pattern of annual CVD deaths
following the differentiated risk threshold by age approach mimics
the policy it resembles at each age interval. For age group 40e49,
the number of deaths is somewhat similar to the ESC approach
where medical CVD prevention is provided in a non-discriminatory
way to all with risk threshold 5%. In age group 50e69, the mor-
tality pattern runs parallel to that of the WHO approach, while at
the oldest age groups, where higher risk thresholds are required for
the initiation of CVD prevention management, the number of CVD
deaths slopes up towards the baseline approach of no medical
prevention for anyone (Fig. 3).
4.2. Gini coefﬁcient, life expectancy, achievement index and total
cost
The life expectancy at 40 resulting from no medical CVD pre-
vention (baseline approach) is 23.3 years, which is the lowest of the
four preventive scenarios analyzed. This approach is also accom-
panied by the highest Gini coefﬁcient and lowest achievement in-
dex. Even though nomedical intervention is modeled, the total cost
of this approach is US$42 million, since we assume full access to
CVD prevention (although for this scenario no CVD prevention is
provided) and management. The cost therefore reﬂects the CVD
management costs incurred when part of the cohort develops CVD.75
Baseline approach
WHO approach (risk threshold 10–19.9%)
DiﬀerenƟated risk threshold by age
ESC approach (risk threshold ≥5–9.9%)
resholds for CVD medical prevention are applied.
Table 2
Gini index, life expectancy, achievement index and total costs of different risk threshold approaches for medical prevention of CVD.
LE at 40 Gini index A-index Total costs (0000US$) No. Treated
Baseline approach 23.3 0.266 17.1 41,700
WHO approach (RT, 10e19.9%) 26.6 0.243 20.1 60,200 487,000
Differentiated risk threshold by age 28.3 0.216 22.2 60,200 567,000
ESC approach (RT,  5e9.9%) 29.2 0.211 23.0 77,700 1,275,000
LE ¼ life expectancy at age 40 years; A ¼ achievement; No ¼ numbers; RT ¼ risk threshold.
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entiated risk threshold by age, are the same, providing CVD pre-
vention by applying the differentiated risk threshold is the best
approach in terms of both efﬁciency (life expectancy at 40 of 28.3
years compared to 26.6 years) and in terms of equality (Gini coef-
ﬁcient 0.216 vs. 0.243), and consequently also when both efﬁciency
and inequality are jointly considered (Table 2). There was no
distributional conﬂict between these two approaches, since the
approach that maximizes health is also the approach that distrib-
uted life expectancies most equitably.
While the ESC approach gave the highest life expectancy at the
age of 40 (29.2 years compared with 26.6 years e WHO approach
and 28.3 yearse differentiated risk threshold approach), it was also
the one that produced the most equitable distribution of health in
terms of remaining life expectancy since its Gini coefﬁcient was
lower (0.211) compared to the WHO (0.243) and the differentiated
risk threshold (0.216) approaches. This translates into this approach
producing the highest achievement index (A ¼ 23.0), followed by
the differentiated risk threshold (A ¼ 22.2) and lastly the WHO
approach (A ¼ 20.1). However, this approach comes with very high
total costs of around US$78 million (Table 2).4.3. Pairwise comparisons between the different CVD prevention
approaches
Providing CVD prevention by differential risk threshold by age
approach resulted in the least cost per life year gained compared to
the baseline approach of no CVD medical prevention (CER ¼ US$
3,761,000 per LY). On the other hand, pairwise comparison be-
tween basing treatment threshold on ESC approach to CVD pre-
vention following differentiated risk threshold approach yielded
the highest cost per life year gained (CER ¼US$ 19,059,000 per LY)
(Table 3).
The differentiated risk threshold approach was also the most
cost-equitable approach compared to the baseline approach with
cost per percentage Gini improvement of US$ 3,698,000. Even
thoughWHO single risk approach had the second least cost per life
year gained compared to the baseline approach, this approach
yielded one of the highest cost per percentage Gini improvement of
US$ 8,103,000 (Table 3).
In both instances differentiated risk threshold approach domi-
nated the WHO single risk approach. With the cost of the two ap-
proaches designed to be the same, the former yielded more life
years and percentage Gini improvement than the latter.Table 3
Pairwise comparisons of the different risk threshold approaches for medical prevention
Incr. TC (0000 US$) Incr. LY gained % Gini improv
WHO versus Baseline 18,542 3.22 2.29
DRT versus Baseline 18,542 4.93 5.01
ESC versus Baseline 35,966 5.84 5.47
DRT versus WHO 0 1.71 2.73
ESC versus WHO 17,425 2.63 3.18
ESC versus DRT 17,425 0.91 0.45
Incr¼ Incremental; TC¼ Total costs; LY¼ Life year; WHO¼WHO approach (RT, 10e19.9%
risk threshold by age; ESC ¼ ESC approach (RT,  5e9.9%); vs ¼ versus.5. Discussion
In this work we have shown that the absolute risk approach by
differentiated risk thresholds brings about more and fairer health
compared to the absolute risk approach by single risk threshold
recommended by the WHO when the total costs of the two ap-
proaches are the same. When compared with the baseline
approach, differentiated risk threshold approach is the best in
terms of life expectancy maximization and inequality reduction
while WHO single risk threshold yielded higher cost per life year
gained and cost per percentage Gini improvement respectively.
The paper builds upon the recommendations for CVD preven-
tion in Norway, which proposes a shift from ESC guidelines to the
application of a differentiated risk threshold by age. This work goes
one step further by modeling the different risk threshold ap-
proaches and by explicitly estimating their equality impact.
Nevertheless, some comparisons can be made with the results of
the analysis exploring the potential implications of the Norwegian
guidelines (Norheim, 2014). They showed that life years gained
from primary medical prevention of CVD would be more equally
distributed with the differentiated risk threshold approach
compared to the ESC's single risk threshold approach. In this work,
we found similar results when comparing the differentiated risk
threshold approach to the WHO's single risk threshold approach.
However, these two works differ in some important respects.
Firstly, the Norwegian recommendations use different risk
threshold cut-offs of 1%, 5% and 10% for 0e49, 0e59 and 0e69 age
groups, respectively, for their differentiated risk threshold
approach and, secondly, their distribution of CVD risk levels was
based on country-speciﬁc data.
The achievement index makes equity-efﬁciency trade-offs
explicit. The formulation hinges on the value of the parameter v,
which reﬂects the relative weight that a decision-maker or analyst
assigns to the health of the different groups. In most cases, the
value of v is unknown. For illustrative purposes, and following what
is mostly used in the literature, we set the parameter v ¼ 2. A
sensitivity analysis using alternative inequality aversion parame-
ters would be possible, and is in general advised (Johansson and
Norheim, 2011; O'Donnell Owen et al., 2007; Wagstaff, 2002a).
However, this was not necessary in this case, since the differenti-
ated threshold approach is dominating the other alternatives in
terms of efﬁciency and equity impact, therefore different inequality
aversion parameters would not change the main result. If our re-
sults had shown a distributive conﬂict between maximization and
equity, such a sensitivity analysis would have been obligatory.of CVD.
ement Cost/LY gained (000’ US$) Cost/% Gini improvement (000’ US$)
5760 8103
3761 3698
6154 6577
dominant dominant
6636 5478
19,059 38,330
); Baseline¼ Baseline approach of no medical CVD prevention; DRT¼ Differentiated
F.N. Ngalesoni et al. / Social Science & Medicine 170 (2016) 208e217214Nevertheless, empirical studies from Tanzania are needed to inform
the choice of v, because different populations are likely to have
different rates of trade-off between inequality and efﬁciency.
In this work we use a univariate approach to inequality analysis,
which has the advantages of providing an overall picture of in-
equalities in age at death when different CVD management risk
thresholds are applied and is likely to be comparable if similar
studies are undertaken in other settings (Asada, 2013). However,
determining changes in inequalities between social groups is
important in this setting, in which policies usually aim for socio-
economic redistribution (James et al., 2005). Combining univari-
ate and bivariate analysis would be an interesting next step (Asada,
2013; Fleurbaey and Schokkaert, 2009).
This study has several limitations. Firstly, even thoughwe showed
that primary prevention of CVD in most cases is cost-effective in
Tanzania (Ngalesoni et al., 2016), the different approaches in their
implementation have different cost implications. When comparing
these optionswith different costs, for instanceWHO approach versus
baseline approach or differentiated risk threshold approach versus
the ESC approach, one would ideally take into account not only the
health inequality impact of health beneﬁts (included in this analysis)
but also the health inequality impact of other possible uses of the
given budget. Secondly, the analysis is limited to overall inequality,
withoutdisentangling fair fromunfair inequality. Such considerations
would have required additional information on socioeconomic sta-
tuses, individual responsibility and so on. Thirdly, due to data limi-
tations wemade no adjustment for impacts on health-related quality
of life and focused only on life expectancy. Fourly, our assumption of
nomedical CVDprevention for the baseline approacheeven though it
may resemble current situation in Tanzaniaemay not be entirely true
for the time horizon of 40 years considered in this work. Ideally,
current and future trends in privately funded CVD prevention could
have been included to informamore realistic scenario. Fifth,we relied
on theWHO's Africa region E distribution of CVD risk levelsedue to a
lack of country-speciﬁc dataewhich are estimated from countries
with signiﬁcant diversity in terms of demographic, epidemiological,
socio-economic and policy contexts. The results should therefore be
interpreted with cautionwhen used in this setting. Nevertheless, we
believe that thehighprevalenceofCVDrisk factors currentlyobserved
in Tanzania is not very different from the situation in other SSA con-
texts. Lastly, our modeling of total cost did not follow standardguidelines for a budget impact analysis (Mauskopf et al., 2007;
Sullivan et al., 2014). We relied on a simpliﬁed approach for esti-
mating the total costs, whichmay not reﬂect all costs or economies of
scale, accurately. More work needs to be done on implementation
costs before policy implications can be drawn.6. Conclusions
This work illustrates that evidence on costs and outcomes
within a disease area in a low-resource setting can be used to es-
timate impact on and distribution of life expectancy using standard
summary measures of population health. Under constant and
limited budgets, and if concerns for efﬁciency and equal distribu-
tion are both important, then the differentiated risk threshold by
age is the better approach compared to the single risk threshold of
10e19.9% recommended by the World Health Organization guide-
lines. However, more research is required on the country-speciﬁc
distribution of cardiovascular risk levels and a budget impact
analysis to assess the feasibility of its implementation.Acknowledgements
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Appendix 1
WHO/ISH risk prediction chart for AFR E. 10-year risk of a
cardiovascular event by gender, age, systolic blood pressure and
smoking status in settings where blood cholesterol can (Appendix
1a) and cannot (Appendix 1b) be measured.
Reproduced with permission from WHO Prevention of Cardio-
vascular Disease, Pocket Guidelines for Assessment and Management
of Cardiovascular Risk, reference: (World Health Organization, 2007)
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SCORE chart: 10-year risk of fatal cardiovascular disease (CVD)
in countries at high CVD risk based on the following risk factors:
age, sex, smoking, systolic blood pressure, and total cholesterol.Reproduced from Piepoli MF, Hoes AW, Agewall S et al., 2016.
European Guidelines on cardiovascular disease prevention in clin-
ical practice. European Heart Journal Aug 2016, 37 (29) 2315e2381;
http://dx.doi.org/10.1093/eurheartj/ehw106 with permission ofOxford University Press (UK) (c) European Society of Cardiology,
www.escardio.org/
“This content is not covered by the terms of the Creative Com-
mons licence of this publication. For permission to reuse, please
contact the rights holder”.
F.N. Ngalesoni et al. / Social Science & Medicine 170 (2016) 208e217216Appendix 3Table A.3. CVD risk level distribution for WHO Africa region E and Tanzania population size based on census 2012
CVD risk level* 40e49 50e59 60e69 70þ Source
CVD risk level distribution
Low (5e9.9%) 0.9538 0.8333 0.6890 0.5683 (World Health Organization, 2007)
Moderate (10e19.9%) 0.0422 0.1193 0.1148 0.1842
High (20e29.9%) 0.0271 0.0608 0.1121 0.1394
Estimated number of individuals at each level of CVD risk
Low (5e9.9%) 415,529 205,284 110,991 56,663 (National Bureau of Statistics Tanzania, 2013)
Moderate (10e19.9%) 73,539 117,558 73,973 73,464
High (20e29.9%) 24,107 42,081 44,462 37,488
*Index cohort characteristics for low CVD risk level (female, SBP of 120e139 mmHg, non-smoker, total cholesterol level of 4 mmol, non-diabetic); moderate CVD risk level
(female, SBP of 150e169 mmHg, smoker, total cholesterol level of 6 mmol for age groups 40e49 and 50e59 and 5 mmol for age groups 60e69 and 70þ, non-diabetic); high
CVD risk level (male, SBP of 150e169 mmHg, non-smoker, total cholesterol level of 8 mmol, non-diabetic); SBP ¼ systolic blood pressure.References
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